Biomarkers of depressive disorders: A multiplex analysis of blood serum

2017 ◽  
Vol 41 (S1) ◽  
pp. S524-S524 ◽  
Author(s):  
A.S. Boiko ◽  
I.S. Losenkov ◽  
L.A. Levchuk ◽  
G.G. Simutkin ◽  
N.A. Bokhan ◽  
...  
Keyword(s):  
Treatment Response ◽  
Depressive Disorders ◽  
Rating Scales ◽  
Rating Scale ◽  
Basic Research ◽  
Serum Markers ◽  
Control Group ◽  
Clinical Indicators ◽  
Feasible Option ◽  
Potential Biomarkers

Depressive disorders are a great burden for individual patients and society. Blood-based biomarkers are regarded as a feasible option for investigation of depressive disorders. Several potential biomarkers for depression were selected. We studied the following serum markers: cortisol, melatonin, brain-derived neurotrophic factor (BDNF), prolactin, insulin-like growth factor 1 (IGF-1), β-endorphin, orexin A. The patient sample consisted of 78 persons with depressive disorders. Patients were divided into two groups: 46 patients with a first depressive episode and 32 patients with recurrent depressive disorder. Control group consisted of 71 healthy individuals of corresponding age and sex. All markers were measured in serum using MILLIPLEX® MAP panels (Merck, Darmstadt, Germany) by analyzer MAGPIX (Luminex, USA). Statistical analyses were performed using SPSS software. Results were expressed as median and quartile intervals [Q1–Q3]. There was a significant increase of serum concentrations of cortisol (663.69 [467.5–959.49] nmol/L, Р < 0.001) and melatonin (66.31 [33.6–132.59] pg/mL, P = 0.029) in patients compared with the control group (526.1 [367,24–654,7] nmol/L and 45.11 [27.47–73.47] pg/mL). In addition, correlations were found between potential biomarkers, clinical indicators and treatment response measured by applying the Hamilton Depression rating scale and the Clinical Global Impression rating scales. A significant correlation was found between the concentration of prolactin and high response to pharmacotherapy (r = –0.267, P = 0.029). Identifying biomarkers that can be used as diagnostics or predictors of treatment response in people with depressive disorders will be an important step towards being able to provide personalized treatment.Disclosure of interestThe work is supported by the project of Russian Foundation of Basic Research No 14-04-01157a.

scholarly journals Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years

2008 ◽  
Vol 52 (9) ◽  
pp. 1448-1451 ◽  
Author(s):  
Pedro Weslley Rosario
Keyword(s):  
Rating Scale ◽  
Serum Markers ◽  
Control Group ◽  
Subclinical Hyperthyroidism ◽  
Mineral Density ◽  
Heart Abnormalities ◽  
The Mean ◽  
Markers Of Bone Formation ◽  
Symptoms And Signs ◽  
Symptom Rating

The objective of the present study was to evaluate bone and cardiac abnormalities and symptoms and signs of thyroid hormone excess in women with subclinical hyperthyroidism (SCH) aged < 65 years. Forty-eight women with SCH were evaluated. The control group consisted of 48 euthyroid volunteers. The mean symptom rating scale score was significantly higher in patients. Cardiac involvement, both morphological and affecting systolic and diastolic functions, was also observed in patients. Women with SCH showed a significant increase in serum markers of bone formation and resorption. In addition, bone mineral density (BMD) was lower in the femoral neck but not in the lumbar spine in patients before menopause, whereas a lower BMD was observed at both sites in postmenopausal patients. SCH is not completely asymptomatic in women aged < 65 years, and is associated with heart abnormalities and with increased bone turnover and reduced BMD even before menopause.

scholarly journals Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression

2019 ◽  
Vol 11 (2) ◽  
pp. 71-77
Author(s):  
L. I. Abramova ◽  
G. P. Panteleeva ◽  
I. Yu. Nikiforova ◽  
T. E. Novozhenova
Keyword(s):  
Depressive Disorders ◽  
Rating Scales ◽  
Rating Scale ◽  
Treatment Cycle ◽  
Endogenous Depression ◽  
Good Effect ◽  
Antidepressant Effect ◽  
Antidepressive Effect ◽  
Wide Range ◽  
Days Of Therapy

Objective: to develop and justify differentiated indications for the use of agomelatine (valdoxan) to treat the typological variants of endogenous depressions with varying severity on the basis of an analysis of its therapeutic efficacy.Patients and methods. An open prospective study was conducted using the clinical, psychopathological, and psychometric rating scales: the Hamilton Depression Rating Scale (HAMD-21); Udvalg for Kliniske Undersњgelser Scale (UKU); the Snaith-Hamilton Pleasure Scale (SHAPS) for assessing anhedonic disorders, and statistical methods. Examinations were made in 56 patients (mean age, 34.9 years) with moderate and severe endogenous depression within affective psychosis (n=42) and shift-like schizophrenia (n=14) (ICD-10 items F31.3–4; F32.1–2, and F33.1–2). The patients received a cycle treatment with agomelatine (valdoxan) 25–50 mg once a day in the evening for 4–8 weeks. The patients' status was evaluated over time on fixed days from a reduction in the mean total score (MTS) of the respective scales as insignificant (less than 19% reduction in disorders), moderate (20–49%), good (50–69%), and excellent (70% or more) effects. The effect of agomelatine was analyzed in two patient groups. The specific features of the antidepressive effect and its dynamics in the presence of endogenous depressions of different typologies (melancholic, anxious, and adynamic depressions) were studied in Group 1 (n=26); the effect of agomelatine on anhedonic endogenous depressions and manifestations of anhedonia in different mental activity areas (interests, social activity, emotional engagement and eating/drinking) was investigated in Group 2 (n=30).Results and discussion. There was a good tolerance and a high antidepressant activity of agomelatine during its treatment cycle for moderate and severe endogenous depressions. A significant improvement (an 84.4% reduction in HAMD-21 MTS) was noted in patients at 3 and 4 weeks of the treatment cycle and consistently persisted at a subsequent follow-up. Agomelatine showed a good effect (a 50% or more reduction in HAMD-21 MTS) just at 14 days of therapy. The drug was observed to have a balanced antidepressant effect, significant thymoleptic, stimulant, anxiolytic, and antianhedonic activities (reductions in the MTS of depressive disorders by 90.83, 84.9, 82.39, and 78.9%, respectively).Conclusion. The universal spectrum of the antidepressive effect of agomelatine, its good tolerability, high efficacy, and rapid improvement makes it the drug of choice in treating a wide range of psychopathological endogenous depressions: melancholic, apatho-adynamic, anxious, and anhedonic ones.

scholarly journals AB0118 REMISSION OF ANXIETY AND DEPRESSIVE DISORDERS IMPROVES HAQ TREATMENT RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1088.1-1088
Author(s):  
A. Abramkin ◽  
T. Lisitsyna ◽  
D. Veltishchev ◽  
O. Seravina ◽  
O. Kovalevskaya ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Depressive Symptoms ◽  
Treatment Response ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Functional Limitations ◽  
Minor Depression ◽  
Factors Associated ◽  
Lower Baseline

Background:Anxiety and depressive disorders (ADD) significantly affect disease activity and functional disability in rheumatoid arthritis (RA) patients. Psychopharmacotherapy (PPT) of ADD attempts to improve RA disease activity and lower progression of functional limitations.Objectives:To determine factors associated with HAQ treatment response in antidepressants-treated RA-patients at five years endpoint.Methods:128 RA-patients (pts) were enrolled, 86% were women with a mean age of 47,4±11,3 (M±SD) yrs. All patients met the full ACR/EULAR 2010 criteria for RA. Functional limitations were assessed using Health Assessment Questionnaire (HAQ), mean HAQ was 1,42±0,78 at baseline. 69,4% RA-pts were already taking prednisone (9 [5; 10] mg/day (Me (25%; 75%)), 84,4% - cDMARDs, 7,8% - bDMARDs (anti-TNF-α – 6,3%, rituximab – 1,6%). ADD were diagnosed by psychiatrist in 123 (96,1%) of RA-pts in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery–Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-pts with ADD were divided into the following treatment groups: 1 – сDMARDs (n=39), 2 – сDMARDs + PPT (sertraline or mianserine) (n=43), 3 – сDMARDs + bDMARDs (n=32), 4 – сDMARDs + bDMARDs + PPT (sertraline or mianserine) (n=9). Biologics treatment duration varied from 1 to 6 years, antidepressants – from 6 to 96 weeks. Baseline HAQ scores were 1,39±0,75, 1,42±0,9, 1,58±0,76 and 1,38±0,83 in groups 1-4, respectively. At 5-yrs endpoint in 83 RA-pts differences between baseline and endpoint HAQ scores (Δ HAQ = endpoint HAQ – baseline HAQ) were assessed as HAQ treatment response with minimal clinically important difference (MCID) (Δ HAQ ≥ 0,22). HAQ response rates were 4,2%, 65,5%, 47,6% and 76,7% in groups 1-4, respectively, with the lowest response rate in group 1 (p<0,0001). Logistic regression analysis was conducted to determine factors associated with RA remission rate.Results:By univariate logistic regression, anxiety and depressive symptoms remission at 5-yrs endpoint, baseline HAQ and major depression, lower baseline age, BMI and DAS28, no minor depression and cardiovascular diseases at baseline were significantly (p≤0,2) associated with HAQ treatment response (table 1). These variables were subjected to multivariate stepwise logistic regression. Only remission of anxiety and depressive symptoms at 5-yrs endpoint (OR 6,6 (95%CI 1,78 – 24,43), p=0,005), higher baseline HAQ (OR 2,61 (95%CI 1,12 – 6,11), p=0,027) and lower baseline BMI (OR 0,9 (95%CI 0,85 – 0,96), p=0,001) were independently associated with HAQ treatment response at 5-years follow-up.Table 1.Factors associated with RA remission at 5 years (univariate logistic regression).FactorpOR95%CIlowupAnxiety and depressive symptoms remission at 5-yrs endpoint0,0075,01,56116,016Baseline HAQ0,012,6571,2645,588Baseline major depression0,1422,0820,7825,542Baseline age0,0980,9920,9821,002Body mass index (BMI)0,0480,9810,9631,0Baseline minor depression0,1670,5630,2491,273Cardiovascular diseases0,10,4170,1471,183Baseline DAS280,0080,0771,0712,096Conclusion:higher HAQ and lower BMI at baseline and remission of anxiety and depressive symptoms at 5-yrs endpoint are independently associated with HAQ treatment response (MCID) at 5-years follow-up.Disclosure of Interests:None declared

scholarly journals Public perceptions of adult ADHD: Indications of stigma?

2020 ◽  
Author(s):  
Emmet Godfrey ◽  
Anselm B. M. Fuermaier ◽  
Lara Tucha ◽  
Marah Butzbach ◽  
Matthias Weisbrod ◽  
...  
Keyword(s):  
Mental Disorders ◽  
Adult Adhd ◽  
Rating Scales ◽  
Rating Scale ◽  
Public Perceptions ◽  
Medium Effect ◽  
Control Group ◽  
Adhd Group ◽  
Major Barrier ◽  
Dsm Iv

AbstractStigmatization represents a major barrier to treatment seeking across mental disorders. Despite this, stigma research on individual mental disorders remains in its infancy. Attention-deficit hyperactivity disorder (ADHD) in adults also represents an under-researched area—being far less studied than its child counterpart. This study examined the current state of public perceptions towards adult ADHD. A simulation group consisting of 105 participants performed the Weiss Functional Impairment Rating Scale (WFIRS) and Conners’ Adult ADHD Rating Scales (CAARS) as though they had ADHD. These scores were compared to a group consisting of 98 individuals with adult ADHD and a group of 117 healthy individuals both groups being instructed to complete the WFIRS and CAARS to the best of their abilities. Simulators were found to overestimate impairments in adult ADHD (to a large effect) in the domains of hyperactivity, DSM-IV hyperactivity-impulsivity, DSM-IV total, work, school, (to a medium effect) in family and social, and (to a negligible-small effect) in inattention, impulsivity, DSM-IV inattention, and life skills when compared to the ADHD group, and in all domains (to a large effect) when compared to the control group. Current and retrospective ADHD symptoms were found to be associated with more accurate perceptions in a number of domains. Evidence for the presence of perceptions considered to be stigmatizing was found, with largest effects present in the domains of hyperactivity, impulsivity, impairments at work, school, and engagement in risky behaviour.

scholarly journals The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis

2014 ◽  
Vol 369 (1645) ◽  
pp. 20130427 ◽  
Author(s):  
Simon Blankley ◽  
Matthew Paul Reddoch Berry ◽  
Christine M. Graham ◽  
Chloe I. Bloom ◽  
Marc Lipman ◽  
...  
Keyword(s):  
Public Health ◽  
Antimicrobial Resistance ◽  
Infectious Diseases ◽  
Treatment Response ◽  
Host Response ◽  
Basic Research ◽  
Treatment Monitoring ◽  
Adequate Treatment ◽  
Health Measures ◽  
Potential Biomarkers

Despite advances in antimicrobials, vaccination and public health measures, infectious diseases remain a leading cause of morbidity and mortality worldwide. With the increase in antimicrobial resistance and the emergence of new pathogens, there remains a need for new and more accurate diagnostics, the ability to monitor adequate treatment response as well as the ability to predict prognosis for an individual. Transcriptional approaches using blood signatures have enabled a better understanding of the host response to diseases, leading not only to new avenues of basic research, but also to the identification of potential biomarkers for use in diagnosis, prognosis and treatment monitoring.

scholarly journals Expression of Selected Genes Involved in Neurogenesis in the Etiopathogenesis of Depressive Disorders

2021 ◽  
Vol 11 (3) ◽  
pp. 168
Author(s):  
Katarzyna Bliźniewska-Kowalska ◽  
Piotr Gałecki ◽  
Janusz Szemraj ◽  
Monika Talarowska
Keyword(s):  
Gene Expression ◽  
Neurotrophic Factor ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Mrna Levels ◽  
Depressed Patients ◽  
Gdnf Gene ◽  
Glial Derived Neurotrophic Factor

(1) Background: The neurogenic theory suggests that impaired neurogenesis within the dentate gyrus of the hippocampus is one of the factors causing depression. Immunology also has an impact on neurotrophic factors. The aim of the study was to assess the importance of selected genes involved in the process of neurogenesis i.e., nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and neuron-restrictive silencer factor (REST gene) in the etiopathogenesis of depressive disorders. (2) Methods: A total of 189 subjects took part in the study (95 depressed patients, 94 healthy controls). Sociodemographic data were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). RT-PCR was used to assess gene expression at the mRNA levels, while Enzyme-Linked Immunosorbent Assay (ELISA) was used to assess gene expression at the protein level. (3) Results: Expression of NGF, BDNF, REST genes is lower in depressed patients than in the control group, whereas the expression of GDNF gene is higher in patients with depressive disorders than in the group of healthy volunteers. (4) Conclusions: The expression of selected genes might serve as a biomarker of depression.

scholarly journals Kriya Yoga in Patients with Depressive Disorders: A Pilot Study

2021 ◽  
Vol 12 (02) ◽  
pp. 362-367
Author(s):  
Ananya Srivastava ◽  
Pooja P. Kuppili ◽  
Tanu Gupta ◽  
Naresh Nebhinani ◽  
Ambika Chandani
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Remission Rate ◽  
Intervention Group ◽  
Control Group ◽  
Major Depressive ◽  
Yoga Intervention ◽  
Severity Of Depression

Abstract Background and Objectives Despite the easy acceptability and holistic nature of Kriya yoga, there are no studies evaluating the role of Kriya yoga intervention on depression. The objective of the current study was to assess the feasibility and effect of adjunctive Kriya yoga on depression. Methods Patients with major depressive disorder who opted for Kriya yoga were recruited into the intervention group (adjunctive Kriya yoga) and those on psychotropic medication alone were enrolled into the control group. The Hamilton Depression Rating Scale (HDRS) measurements were recorded at baseline, end of 2, 4, and 8 weeks. Results HDRS scores of the intervention group (n = 29) were found to be significantly lesser than that of the control group (n = 52) by the end of 2, 4, and 8 weeks. The remission rate was also significantly greater in the intervention group. Conclusion Kriya yoga intervention was found to be feasible, as well as improved the severity of depression.

scholarly journals Emotions as a state and as a trait in people with depressive disorders*

2019 ◽  
Vol 73 ◽  
pp. 721-728
Author(s):  
Aleksandra Skiba ◽  
Paulina Maruszewska ◽  
Monika Talarowska ◽  
Piotr Gałecki
Keyword(s):  
Psychosocial Functioning ◽  
Depressive Episode ◽  
Positive Emotions ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Negative Emotions ◽  
Healthy People ◽  
Control Group ◽  
The People ◽  
Positive And Negative Emotions

Depression is a disorder involving a number of changes in human psychosocial functioning. The aim of this study is to evaluate the intensity of positive and negative emotions understood both as a state and a permanent personality trait in people with depressive disorders and to determine whether the intensity of positive and negative emotions differentiates healthy people from people suffering from depressive disorders. The study was conducted on 107 individuals – 67 people from the experimental group suffering from depressive disorders and 40 people from the control group with a negative interview in terms of mental and somatic disorders. The following tools were used: Hamilton Depression Rating Scale (evaluation of severity of depressive symptoms), STAI Questionnaire (evaluation of anxiety severity as a state and trait) and PANAS Questionnaire (intensity of negative and positive emotions as a state and trait). A significantly higher intensity of positive emotions understood both as a state and a trait was observed in the people not suffering from depression, while the opposite results were obtained with regard to negative emotions, i.e. the individuals suffering from depression recorded lower scores than the healthy persons. It was also shown that the people with depression had higher scores in terms of the level of anxiety as a state and trait. The intensity of positive emotions as a state was significantly higher among the people with the first depressive episode in comparison to the people with recurrent depressive disorders. The severity of depression correlated positively with the intensity of negative emotions as a state both at the time of inclusion in the study and after obtaining a response to the applied pharmacological treatment. Experienced positive and negative emotions, understood both as a state and as a trait, differentiate not only individuals with depression from healthy people, but also patients with the first depressive episode and those with recurrent depressive disorders.

scholarly journals Electroacupuncture and Cognitive Behavioural Therapy for Sub-Syndromal Depression among Undergraduates: A Controlled Clinical Trial

2016 ◽  
Vol 34 (5) ◽  
pp. 356-363 ◽  
Author(s):  
Tianwei Guo ◽  
Zhuo Guo ◽  
Wenyue Zhang ◽  
Wenhao Ma ◽  
Xinjing Yang ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Cognitive Behavioural Therapy ◽  
Depressive Disorders ◽  
Rating Scale ◽  
Remission Rate ◽  
Behavioural Therapy ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Cognitive Behavioural ◽  
Increased Risk

Background Individuals with sub-syndromal depression (SSD) are at increased risk of incident depressive disorders; however, the ideal therapeutic approach to SSD remains unknown. Objective To evaluate the effects of electroacupuncture (EA) and cognitive behavioural therapy (CBT), alone or in combination, on depressive symptoms. Methods Undergraduate students with SSD were recruited and allocated to one of four groups based on their preferences: EA (n=6), CBT (n=10), EA+CBT (n=6), and untreated control (n=11) groups. Six weeks of treatment were provided in the first three groups. Clinical outcomes were measured using the 17-item Hamilton Depression (HAMD-17) rating scale, Center for Epidemiologic Depression (CES-D) scale, WHO Quality of Life-Brief version (WHOQOL-BREF) questionnaire, and clinical remission rate. Results All 33 subjects were included in an intent-to-treat analysis. Statistically significant improvements in HAMD-17, CES-D, and WHOQOL-BREF scores and a higher remission rate were found in the EA, CBT, and EA+CBT intervention groups compared with the control group (all p<0.05). No significant differences were found between the three intervention groups. HAMD-17 factor score analysis revealed that EA reduced sleep disturbance scores more than CBT or EA+CBT (p<0.05), and CBT reduced retardation scores more than EA (p<0.01). EA+CBT reduced anxiety/somatisation scores more than EA or CBT (p<0.05) and retardation scores more than EA (p<0.05). Conclusions Early intervention may alleviate depressive symptoms in SSD. EA and CBT may have differential effects on certain symptoms. Combination therapy targeting both physical and psychological symptoms may represent an ideal strategy for SSD intervention. However, randomised trials with larger sample sizes are needed. Trial Registration Number ChiCTR-TRC-10000889; Results.

scholarly journals Defense Mechanisms and Treatment Response in Depressed Inpatients

2021 ◽  
Vol 12 ◽  
Author(s):  
Yves de Roten ◽  
Slimane Djillali ◽  
Fabienne Crettaz von Roten ◽  
Jean-Nicolas Despland ◽  
Gilles Ambresin
Keyword(s):  
Treatment Response ◽  
Psychodynamic Psychotherapy ◽  
Defense Mechanisms ◽  
Rating Scales ◽  
Rating Scale ◽  
Defense Mechanism ◽  
Symptomatic Improvement ◽  
Inpatient Setting ◽  
Therapy Program ◽  
Defensive Functioning

The study investigated the extent to which defensive functioning and defense mechanisms predict clinically meaningful symptomatic improvement within brief psychodynamic psychotherapy for recurrent and chronic depression in an inpatient setting. Treatment response was defined as a reduction in symptom severity of 46% or higher from the baseline score on the Montgomery–Asberg Depression Rating Scale (MADRS). A subsample of 41 patients (19 responders and 22 non-responders) from an RCT was included. For each case, two sessions (the second and the penultimate) of brief inpatient psychodynamic psychotherapy (a manualized 12-session therapy program developed in Lausanne) were transcribed and then coded using the Defense Mechanism Rating Scales (DMRS) and the Psychotic Defense Mechanism Rating Scales (P-DMRS), an additional scale developed to study psychotic defenses. Results showed that defensive functioning and mature and immature defense changed during psychotherapy and predicted treatment response. Patient’s defenses observed throughout therapy also predicted treatment response at 12-month follow-up. The addition of psychotic defenses allows a better prediction of the treatment response. Overall, these results are in line with previous research and provide further validation of defensive functioning as a predictor of outcomes and a mechanism of change in psychotherapy.

Sign in / Sign up

Export Citation Format

Share Document